Anti-FLAP antibody (ab85227)
Key features and details
- Rabbit polyclonal to FLAP
- Suitable for: WB, ICC/IF
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-FLAP antibody
See all FLAP primary antibodies -
Description
Rabbit polyclonal to FLAP -
Host species
Rabbit -
Tested Applications & Species
See all applications and species dataApplication Species ICC/IF HumanWB Human
-
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- This antibody gave a positive signal in Human small intestine tissue lysate as well as the following whole cell lysates: U937; THP1.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.
One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.
Learn more here.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituent: PBS
Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help. -
Concentration information loading... -
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab85227 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Guaranteed
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted
Predicted to work for this combination of applications and species but not guaranteed.
Incompatible
Does not work for this combination of applications and species.
| Application | Species |
|---|---|
| ICC/IF |
Human
|
| WB |
Human
|
| All applications |
Mouse
Rabbit
Horse
Cow
Macaque monkey
|
| Application | Abreviews | Notes |
|---|---|---|
| WB | (1) |
Use a concentration of 1 µg/ml. Detects a band of approximately 14 kDa (predicted molecular weight: 14 kDa).
|
| ICC/IF |
Use a concentration of 5 µg/ml.
|
| Notes |
|---|
|
WB
Use a concentration of 1 µg/ml. Detects a band of approximately 14 kDa (predicted molecular weight: 14 kDa). |
|
ICC/IF
Use a concentration of 5 µg/ml. |
Target
-
Function
Required for leukotriene biosynthesis by ALOX5 (5-lipoxygenase). Anchors ALOX5 to the membrane. Binds arachidonic acid, and could play an essential role in the transfer of arachidonic acid to ALOX5. Binds to MK-886, a compound that blocks the biosynthesis of leukotrienes. -
Involvement in disease
Genetic variations in ALOX5AP may be a cause of susceptibility to ischemic stroke (ISCHSTR) [MIM:601367]; also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.
Note=Genetic variations in ALOX5AP may be associated with susceptibility to myocardial infarction. Involvement in myocardial infarction is however unclear: according to some authors (PubMed:14770184), a 4-SNP haplotype in ALOX5AP confers risk of myocardial infarction, while according to other (PubMed:17304054) ALOX5AP is not implicated in this condition. -
Sequence similarities
Belongs to the MAPEG family. -
Domain
The C-terminal part after residue 140 is mostly unstructured. -
Cellular localization
Nucleus membrane. Endoplasmic reticulum membrane. - Information by UniProt
-
Database links
- Entrez Gene: 100034178 Horse
- Entrez Gene: 241 Human
- Entrez Gene: 11690 Mouse
- Entrez Gene: 100009413 Rabbit
- Omim: 603700 Human
- SwissProt: P30353 Horse
- SwissProt: P20292 Human
- SwissProt: P30355 Mouse
see all -
Alternative names
- 5-lipoxygenase activating protein antibody
- AL5AP_HUMAN antibody
- ALOX 5AP antibody
see all
Images
-
Western blot - Anti-FLAP antibody (ab85227)All lanes : Anti-FLAP antibody (ab85227) at 1 µg/ml
Lane 1 : U937 (Human leukemic monocyte lymphoma cell line) Whole Cell Lysate
Lane 2 : THP1 (Human acute monocytic leukemia cell line) Whole Cell Lysate
Lane 3 : Human small intestine tissue lysate - total protein (ab29276)
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 14 kDa
Observed band size: 14 kDa
Additional bands at: 175 kDa, 75 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 20 minutes -
Immunocytochemistry/ Immunofluorescence - Anti-FLAP antibody (ab85227)ICC/IF image of ab85227 stained MCF7 cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab85227, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899 Dylight 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (8)
ab85227 has been referenced in 8 publications.
- Werner M et al. Targeting biosynthetic networks of the proinflammatory and proresolving lipid metabolome. FASEB J 33:6140-6153 (2019). PubMed: 30735438
- Rao Z et al. Vacuolar (H+)-ATPase Critically Regulates Specialized Proresolving Mediator Pathways in Human M2-like Monocyte-Derived Macrophages and Has a Crucial Role in Resolution of Inflammation. J Immunol 203:1031-1043 (2019). PubMed: 31300512
- Oddi S et al. The anti-inflammatory agent bindarit acts as a modulator of fatty acid-binding protein 4 in human monocytic cells. Sci Rep 9:15155 (2019). PubMed: 31641194
- Pein H et al. Endogenous metabolites of vitamin E limit inflammation by targeting 5-lipoxygenase. Nat Commun 9:3834 (2018). PubMed: 30237488
- Werz O et al. Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Nat Commun 9:59 (2018). WB, IF ; Human . PubMed: 29302056
- Garscha U et al. Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase. Sci Rep 7:9398 (2017). ICC/IF . PubMed: 28839250
- Pace S et al. Androgen-mediated sex bias impairs efficiency of leukotriene biosynthesis inhibitors in males. J Clin Invest 127:3167-3176 (2017). PubMed: 28737505
- Garscha U et al. BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly. Biochem Pharmacol 119:17-26 (2016). PubMed: 27592027